Evaluation of the Automatic Deformable Recontouring on the Daily MVCT for Head and Neck Cancer Adaptive Radiotherapy (GIRAFE)

April 10, 2026 updated by: Institut Claudius Regaud

This trial is a prospective, monocentric study aiming to evaluate an adaptive radiotherapy method (automatic deformable recontouring on the daily MVCT (MegaVoltage Computerized Tomography)) using the Precise ART™ software in patients with head and neck cancer.

Patients will receive helical intensity-modulated radiotherapy (IMRT) according to the standard recommendations (35 fractions during 7 weeks). Radiotherapy will include daily repositioning MVCT.

For the study, patients will undergo 4 intermediate re-planning CT-scan (without injection of intravenous contrast agent) at week 3, week 4, week 5 and week 6 of treatment.

3 recontouring modalities will be evaluated for the study:

  • Manuel recontouring (standard method)
  • Precise ART™ deformed contours
  • Precise RTX™ deformed contours

The total duration of the study for each patient will be 7 weeks.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Toulouse, France
        • Institut Universitaire Du Cancer Toulouse - Oncopole (Iuct-O)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age ≥ 18 years old
  2. Patient with histologically proven locally advanced head and neck cancer (Oropharynx, hypopharynx, larynx, nasopharynx, oral cavity, sinuses, nasal cavities, ethmoid sinus, cavum, salivary glands)
  3. Cancer with nodal involvement (at least T3 or involved node >2 cm)
  4. Eastern Cooperative Oncology Group performance status 0 or 1
  5. No previous curative treatment for head and neck cancer (surgery and/or radiotherapy and/or chemotherapy)
  6. Indication of exclusive radiotherapy (+/- chemotherapy) validated in multidisciplinary meeting
  7. Patient affiliated to the french social security system.
  8. Patient must provide written informed consent prior to inclusion in the study and any study-specific procedure.

Exclusion Criteria:

  1. Patient with metastatic cancer
  2. Eastern Cooperative Oncology Group performance status ≥ 2 (due to comorbidities)
  3. Patient with recurrent disease
  4. Patient who required urgent surgical treatment
  5. Contraindications to radiotherapy
  6. History of cancer within 5 years
  7. Patient already included in another therapeutic trial
  8. Pregnant or breastfeeding women
  9. Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures
  10. Patient protected by law

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Radiotherapy treatment
Other: Helical intensity-modulated radiotherapy (IMRT)
Helical intensity-modulated radiotherapy (35 fractions, 5 fractions per week) will be administered during 7 weeks: 2 Gy per fraction on tumor and 1.6 Gy per fraction on bilateral lymph node areas.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rate of patients with Dice Similarity Coefficient (DSC) of the volumes of left and right parotid gland superior to 0.85 (DSC > 0.85)
Time Frame: 7 weeks for each patient
7 weeks for each patient

Secondary Outcome Measures

Outcome Measure
Time Frame
Rate of patients with DSC > 0.85 for other organs at risk (oral cavity, medullar canal, mandible,brain stem, larynx)
Time Frame: 7 weeks for each patient
7 weeks for each patient
Rate of patients with DSC > 0.85 for target volumes (clinical target volume, gross target volume, planning target volume)
Time Frame: 7 weeks for each patient
7 weeks for each patient
Time saving defined by the difference between standard recontouring time (manuel recontouring) and experimental recontouring time (Precise ART™ or Precise RTX™)
Time Frame: 7 weeks for each patient
7 weeks for each patient

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut Claudius Regaud

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2019

Primary Completion (Estimated)

January 1, 2021

Study Completion (Estimated)

January 1, 2021

Study Registration Dates

First Submitted

May 14, 2019

First Submitted That Met QC Criteria

May 15, 2019

First Posted (Actual)

May 16, 2019

Study Record Updates

Last Update Posted (Actual)

April 15, 2026

Last Update Submitted That Met QC Criteria

April 10, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 19VADS01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Head and Neck Cancer

Clinical Trials on Helical intensity-modulated radiotherapy (IMRT)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe